ChemBioChem · 2023 · 10 citations · 18 references
PharmacyBiochemistryMedicinal ChemistryCombinatorial ChemistryDrug DesignDrug DiscoveryLinker ChemistryProteolytic EnzymesCross CouplingE3 Ubiquitin Ligase Substrate RecognitionProteasome SystemProteasome-mediated DegradationProtein TargetsSubstrate ScopeTargeted Protein DegradationUbiquitin-mediated Proteolysis
Proteolysis targeting chimeras (PROTACs) are a promising therapeutic strategy to selectively promote the degradation of protein targets by exploiting the ubiquitin-proteasome system. Among the limited number of E3 ligase ligands discovered for the PROTAC technology, ligands of cereblon (CRBN) E3 ligase, such as pomalidomide, thalidomide, or lenalidomide, are the most frequently used for the development of PROTACs. Our group previously reported that a phenyl group could be tolerated on the C4-position of lenalidomide as the ligand of CRBN to develop PROTACs. Herein, we report a modular chemistry platform for the efficient attachment of various ortho-, meta-, and para-substituted phenyls to the C4-position of the lenalidomide via Suzuki cross-coupling reaction, which allows the systematic investigation of the linker effect for the development of PROTACs against any target. We examined the substrate scope by preparing twelve lenalidomide-derived CRBN E3 ligase ligands with different linkers.
18
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Eric S. Fischer, Kerstin Böhm, John R. Lydeard et al. · Nature · 2014 · 1.1K citations · Full text
Yangbing Li, Jiuling Yang, Angelo Aguilar et al. · Journal of Medicinal Chemistry · 2018 · 299 citations · Full text
Medicine, Oncology, Pharmacology +10